Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Transcription factors are believed to have a dominant role in acute myeloid leukemia (AML). This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis, and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutated. However, analysis of knockout animals has not shown a direct link between abrogated transcription factors and the pathogenesis of AML. Sfpi1, encoding the lineage-specific transcription factor PU.1, is indispensable for normal myeloid and lymphoid development. We found that mice carrying hypomorphic Sfpi1 alleles that reduce PU.1 expression to 20% of normal levels, unlike mice carrying homo- or heterozygous deletions of Sfpi1, developed AML. Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. Malignant transformation was associated with a high frequency of clonal chromosomal changes. Retroviral restoration of PU.1 expression rescued myeloid differentiation of mutant progenitors and AML blasts. These results suggest that tightly graded reduction, rather than complete loss, of a lineage-indispensable transcription factor can induce AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preleukemic states (e.g., MDS), where PU.1 downregulation permits clonal expansion 33-35”
From USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization (2026) · cites this paper as [33]
In the citing paper
“In mice, a decrease in Pu.1-mediated differentiation gene activation causes leukemia.22”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [22]
In the citing paper
“Studies in murine models of AML with decreased levels of PU.1 showed an elevated expression of c-Myc.28”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“A reduction in PU.1 expression and activity is commonly seen in mouse and human cases of AML.[28][29][30]”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“Although loss or near-complete loss of the hematopoietic transcription factor PU.1 induces acute myeloid leukemia (AML) in mice”
From Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia (2015) · cites this paper as [9]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We could not separate mutant progenitors into distinct common myeloid progenitor, myeloid-erythroid progenitor and granulocyte-macrophage progenitor subpopulation”
BackgroundSelf-citationOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289 · cited 1×
“F331 Spleen 39,X,-Y[6]/40,idem,+15[2]/41,XY,+15[2]”
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination
Meyers, E. N., Lewandoski, M., & Martin, G. R. (1998) · Nature Genetics · doi:10.1038/ng0298-136 · Cited by 1,031 · cited 1×
“We released a FRT -PGK neo - FRT resistance cassette from pK-11 (ref”
MethodZhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundSelf-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Self-citationReversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Research works printed but not linked: 2
- Iwasaki-Arai, J. et al. C/EBPα deficiency in hematopoiesis induces accumulation of non-malignant myeloblasts mimicking acute myelogenous leukemia. Blood 100, 61a (2002).
- Duprez, E. et al. PU.1 deficiency blocks the production of Common Myeloid and Common Lymphoid Progenitors in both adult and fetal liver myelopoiesis. Blood 100, 61a (2002).
Cited by
Items 401–500 of 518
Mathematical Framework for Hierarchical Cell Identity Control by Collective Enhancer Dynamics
Grishechkin, A., Mukherjee, A., & Karin, O. (2025) · PRX Life · doi:10.1103/dkmq-h4d9 · Cited by 8
Brown, N., Finnon, R., Finnon, P., McCarron, R., Cruz-Garcia, L., O’Brien, G., Herbert, E., Scudamore, C. L., Morel, E., & Badie, C. (2023) · iScience · doi:10.1016/j.isci.2023.107530 · Cited by 5
Haploinsufficient Transcription Factors in Myeloid Neoplasms
Martinez, T. C., & McNerney, M. E. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-013421 · Cited by 5
“However, an 80% reduction in PU.1 by homozygous deletion of an enhancer upstream of PU.1 results in a transplantable AML (150).”
BackgroundRahn, K., Abdallah, A. T., Gan, L., Herbrich, S. M., Sonntag, R., Benitez, O., Malaney, P., Zhang, X., Rodriguez, A. G., Brottem, J., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.195004 · Cited by 5
Regulatory variation: an emerging vantage point for cancer biology
Li, L., Lorzadeh, A., & Hirst, M. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1250 · Cited by 5
Correlation of PU.1 and signal regulatory protein α1 expression in PU.1 transgenic K562 cells
Takahashi, S. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.827 · Cited by 5
“It has been reported that mice carrying hypomorphic PU.1 alleles that reduce PU.1 expression, to 20% of normal levels, developed acute myeloid leukemia (AML) (5).”
InfluentialZerella, J. R., Homan, C. C., Arts, P., Brown, A. L., Scott, H. S., & Hahn, C. N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1183318 · Cited by 6
Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells
Mattes, K., Geugien, M., Korthuis, P. M., Brouwers-Vos, A. Z., Fehrmann, R. S. N., Todorova, T. I., Steidl, U. G., Vellenga, E., & Schepers, H. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.03.003 · Cited by 6
Wheat, J. C., & Steidl, U. G. (2021) · Blood · doi:10.1182/blood.2019004261 · Cited by 6
Lee, S.-A., Ryu, Y.-S., Choi, H.-I., & Han, I. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.31 · Cited by 5
“1 is tightly controlled in hematopoietic cells (Rosenbauer et al., 2004).”
BackgroundVallelonga, V., Gandolfi, F., Zampini, M., Riva, E., Maggioni, G., Ventura, D., Saba, E., Termanini, A., Polletti, S., Prosperini, E., et al. (2026) · Blood · doi:10.1182/blood.2025030760 · Cited by 5
Xu, S., Hong, J., Dongye, M., Lin, J., Xue, R., Huang, Z., Xu, J., Zhang, Y., Leung, A. Y. H., Shen, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416121122 · Cited by 4
“Given that c - MYB hyperactivity and PU.1 deficiency have the ability to initiate preleukemia (14, 17, 18), as well as our observation that both pu.1 G242D/ G242D and c - myb hyper exhibit neutrophil expansion, abnormal development, and other lineage cytopenia, our findings suggest that low Pu.1 or…”
Cytogenetic Diagnosis of Myelodysplastic Syndromes
Olney, H. J., & Beau, M. M. L. (2006) · Springer eBooks · doi:10.1007/3-540-30794-x_6 · Cited by 6
Hu, X., Cai, J., Zhu, J., Lang, W., Zhong, J., Zhong, H., & Chen, F. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109409 · Cited by 4
Barabino, S. M. L., Citterio, E., & Ronchi, A. E. (2021) · Cancers · doi:10.3390/cancers13153753 · Cited by 4
“Notably, children with biallelic mutations in the BRCA2 develop AML in the first decade of life, sometimes with and sometimes without preceding MDS [121].”
BackgroundGonçalves, C. E. D. S., da Silva, R. O., Hastreiter, A. A., Vivian, G. K., Makiyama, E. N., Borelli, P., & Fock, R. A. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109511 · Cited by 4
Improved Models for Animal Research
Sprengel, R., Eshkind, L. G., Hengstler, J. G., & Bockamp, E. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-285-4_3 · Cited by 4
The PU.1 transcription factor induces cyclin D2 expression in U937 cells
Vicari, L., Eramo, A., Manzella, L., Malaguarnera, L., Iannolo, G., Gulisano, M., Maria, R. D., Messina, A., & Vigneri, P. G. (2006) · Leukemia · doi:10.1038/sj.leu.2404447 · Cited by 4
To switch or not to switch: PU.1 expression is the question
Thoms, J. A. I., Pimanda, J. E., & Heidenreich, O. T. (2021) · Blood · doi:10.1182/blood.2021012112 · Cited by 4
“Levels of PU.1 increase during myelopoiesis,6 but expression is reduced in a range of acute myeloid leukemia (AML) cells, particularly those with core binding factor (CBF) fusions [RUNX1ETO caused by t(8;21) or CBFb-MYH11 caused by inv(16)].4,7 Reduced expression, but not complete ablation, in mice leads to AML.6 Conv…”
BackgroundInfluentialWaliullah, A. S. M., Nguyen, T.-A., Dziegielewska, B., Zhang, J., Qiu, K., Tran, M. L., Nguyen, N., Wang, L., Pan, A., Nong, M. K., et al. (2026) · Blood · doi:10.1182/blood.2025030667 · Cited by 3
Self-citationBender, A., Boydere, F., Jayavelu, A. K., Tibello, A., König, T., Aleth, H., zu Hörste, G. M., Vogl, T. J., & Rosenbauer, F. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00295-y · Cited by 6
“Source data are available online for this fi gure. et al, 1998; Rosenbauer et al, 2004; Nutt et al, 2005).”
InfluentialSelf-citationMorii, M., Kubota, S., Iimori, M., Yokomizo‐Nakano, T., Hamashima, A., Bai, J., Nishimura, A., Tasaki, M., Ando, Y., Araki, K., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02276-w · Cited by 3
Decreased PU.1 expression in mature B cells induces lymphomagenesis
Endo, S., Nishimura, N., Toyoda, K., Komohara, Y., Carreras, J., Yuki, H., Shichijo, T., Ueno, S., Ueno, N., Hirata, S., et al. (2024) · Cancer Science · doi:10.1111/cas.16344 · Cited by 4
Self-citationBinod, G. C., Hoyt, L. J., Dovat, S., & Dong, F. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107860 · Cited by 4
Dogan, Y., Ganser, A., Scherr, M., & Eder, M. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.10.006 · Cited by 3
A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo
Nishimura, N., Endo, S., Ueno, S., Ueno, N., Tatetsu, H., Hirata, S., Hata, H., Komohara, Y., Takeya, M., Mitsuya, H., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.124 · Cited by 3
Self-citationMurine Models of Hematopoietic Disease: Pathologic Analysis and Characterization
Lee, B. H., & Kutok, J. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9_3 · Cited by 3
Self-citationPU.1, a Versatile Transcription Factor and a Suppressor of Myeloid Leukemia
Takahashi, S. (2011) · InTech eBooks · doi:10.5772/25853 · Cited by 3
“…carrying hypomorphic PU.1 alleles that reduce PU.1 expression to 20% of its normal levels were reported to develop acute myeloid leukemia (AML) (Rosenbauer et al., 2004), suggesting that disruption of the function of this transcription factor plays a pivotal role in myeloid leukemia biology…”
BackgroundCore binding factor leukemia hijacks T-cell prone PU.1 antisense promoterPreprint
van der Kouwe, E., Heller, G., Czibere, A., Castilla, L. H., Delwel, R., Ruscio, A. D., Ebralidze, A. K., Forte, M., Kazianka, L., Kornauth, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.29.120857 · Cited by 3
Self-citationUSP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization
Shan, H., Zhang, Y., Xiao, X., Wu, W., Wang, Y., Zhu, C., Bai, W., Zhang, Z., Zhai, Y., Yang, L., et al. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.123712 · Cited by 3
“In preleukemic states (e.g., MDS), where PU.1 downregulation permits clonal expansion [33-35], our discovery that USP7 is a critical stabilizer of PU.1 suggests that targeted activation of the USP7-PU.1 axis could represent a novel therapeutic strategy.”
Tebbi, C. K., Yan, J., Sahakian, E., Mediavilla-Varela, M., Pinilla-Ibarz, J. A., Patel, S. J., Rottinghaus, G. E., Liu, R. Y., & Dennison, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910361 · Cited by 3
Retroviral integration sites (RIS) mark cis-regulatory elements
Ng, C. E. L., Ito, Y., & Osato, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.10.008 · Cited by 2
“1 expression which induced a precancerous state leading to acute myeloid leukemia (AML) with frequent cytogenetic aberrations in mice [57].”
BackgroundCEBPA dosage in leukemogenesis
Mercher, T., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2006-09-043059 · Cited by 2
Nakano, H., YANAGITA, A., & Takahashi, S. (2014) · Biomedical Reports · doi:10.3892/br.2014.265 · Cited by 2
Strzałkowska, A., Unrug-Bielawska, K., Bluszcz, A., Sandowska-Markiewicz, Z., Karaszewska, J., Pyśniak, K., Gajewska, M. E., & Wirth-Dzięciołowska, E. (2011) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.60.405 · Cited by 2
Bilbao, E. A. R., & Knott, M. E. (2016) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000276 · Cited by 2
“For this retrospective study paraffin embedded DLBCL lymph node biopsies of 73 untreated patients [38 male median age and range 59 [25-85]; 35 female 59.”
BackgroundMethodDown-Regulation of PU.1 Gene in Pediatric Acute Lymphoblastic Leukemia Patients from South of Iran
Nakhost, B., Nasiri, M., Karimi, M., & Montazeri, S. (2019) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v13i1.321 · Cited by 2
Ueda, K. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.04.001 · Cited by 2
Molecular Genetics of B- and T Lymphocyte Development
Wikström, I. (2006) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 3
Batista, C. R., & DeKoter, R. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101960 · Cited by 2
Liu, C., Zhou, Y., Zhou, L., Tan, F., Liu, H., Qiu, J., Zhu, M., Chen, M., Shen, Z., Tu, J., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115718 · Cited by 1
Bashir, H. S., Binod, G. C., Rahman, A. A., & Dong, F. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf159 · Cited by 1
Arnuk, A., Han, C., Lawal, A. E., Wang, B., Karma, S., Zhang, Z., Yassouf, M. Y., Rajendran, S. H., Chandok, H., Eller, M. L., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady2936 · Cited by 1
Zhang, Y., Yang, M., Yang, S., & Zhang, S. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01741-7 · Cited by 1
“LDTFs (PU.1, IRF8) establish chromatin accessibility from early embryonic stages; CSF1/IL-34 and TGF-β cooperate for initial population expansion; TGF-β-SALL1 convergence stabilizes homeo - static identity during postnatal maturation; and TREM2-APOE-mediated metabolic adaptation coincides with synaptogenesis and myeli…”
InfluentialRetinoic acid–driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD
Liang, W., Xu, D., Zhang, L. F., Qu, Y., Li, L., Zhong, K., Meng, Y., Zhu, J., Wang, S., Tan, L., et al. (2026) · Blood · doi:10.1182/blood.2025032193 · Cited by 1
Lineage-Specific Transcription Factor Aberrations in AML
Mueller, B. U., & Pabst, T. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_7 · Cited by 3
“These animals had normal numbers of HSCs, but an increased myeloid progenitor compartment, and after a short preleukemic phase they frequently developed an aggressive AML [ 63 ].”
BackgroundTranscription Factors in Cancer Stem Cells of the Hematopoietic Lineage
Koschmieder, S., & Tenen, D. G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-933-8_6 · Cited by 1
Self-citationAssessment of HDACi-Induced Protein Cleavage by Caspases
Treude, F., Gladbach, T., Plaster, J., & Hartkamp, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_2 · Cited by 1
“1 expression leads to AML in mouse models [14, 15], suggesting that PU.”
BackgroundOpposing Role, Depending on the Stage, of PU.1 during Erythroid Differentiation
Takahashi, S. (2012) · Journal of Blood & Lymph · doi:10.4172/2165-7831.1000e108 · Cited by 1
“The downregulation of PU.1 was reported to play a role in the pathogenesis of various hematological malignancies, including Acute Myeloid Leukemia (AML) [2], multiple myeloma [3] and Myelodysplastic Syndrome (MDS) [4].”
BackgroundBiology of Chronic and Acute Myeloid Leukemia
Quintás‐Cardama, A., Cortes, J. E., & Kantarjian, H. M. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10028-7 · Cited by 1
Study of Neuropilin-1/Cd304 Expression in Leukemogenesis
Allam, A., Aziz, S. P., & Ali, E. M. (2018) · Journal of Hematology and Oncology Research · doi:10.14302/issn.2372-6601.jhor-18-1938 · Cited by 1
Cytogenetic Diagnosis of Myelodysplastic Syndromes
Olney, H. J., & Beau, M. M. L. (2013) · Springer eBooks · doi:10.1007/978-3-642-36229-3_3 · Cited by 2
Koschmieder, S., & Serve, H. L. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap387 · Cited by 1
Panton, N. (2008) · SUNScholar (Stellenbosch University) · Cited by 3
Pearson, J. D. (2013) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3n697 · Cited by 1
Inflammation and immune-mediated neurobehavioral alterations : a critical role for microglia
Lacabanne, C. (2018) · theses.fr (ABES) · doi:10.70675/41a4e2a3zdbb7z4aa0z899dz9553bb07954b · Cited by 1
Understanding and Targeting Epigenetic Alterations in Acquired Bone Marrow Failure
Abdel-Wahab, O. I. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada599903
“In addition, down-regulation of PU.1 expression results in impaired myeloid differentiation (Rosenbauer et al., 2004; Steidl et al., 2006).”
BackgroundCortés-Lavaud, X., & Odero (2014) · Depósito Académico Digital Universidad de Navarra (University of Navarra)
Characterisation of the leukaemia-associated ETO homologues
Lindberg, S. R. (2006) · Lund University Publications (Lund University)
A model to investigate the oncogenic activity of MLL-fusions in Acute Myeloid Leukaemia
Walf-Vorderwülbecke, V. (2009) · UCL Discovery (University College London) · Cited by 1
Aberrant Transcription Factors in AML
Friedman, A. D. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-322-6_2
Cook, W. D. (2006) · Blood · doi:10.1182/blood-2006-01-0419
Blood and Runx1: got to have it, really need it
Nimer, S. D. (2004) · Blood · doi:10.1182/blood-2004-09-3532
Pulikkan, J. A. (2008) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.10298
Maretty, L., Sibbesen, J. A., & Krogh, A. (2014)
SHORT TITLE: Genistein limits DNA Damage
Souza, L. R., Silva, E., Calloway, E., Küçük, Ö., Rossi, M. R., & McLemore, M. L. (2014)
La protéine HSP110 : rôle dans le développement tumoral et sur l'immunogénicité du cancer colorectal
Berthenet, K. (2015) · theses.fr (ABES) · doi:10.70675/d13e1f9cz45b5z4624za486z25eb1051e73f
THE BIOLOGICAL FUNCTION OF INTERACTING PARTNERS OF ZXD FAMILY PROTEINS
Koneni, R. (2009) · EngagedScholarship @ Cleveland State University (Cleveland State University)
DNA methylation profiles of cytokine and transcription factor genes in immune cells
Bonn, U. U. L. (2008)
Transcription factor regulation of T helper subset function
Awe, O. (2015) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1724
microRNA expression Macrophage development from HSCs requires PU.1-coordinated
Rosenbauer, F., Heinz, S., Bonifer, C., Bakkers, J., Abdelilah‐Seyfried, S., Riemke, P., Lenze, D., & Hoogenkamp, M. (2011)
Self-citationKamath, M. B. (2009) · OhioLink ETD Center (Ohio Library and Information Network)
Aberrant Transcriptional Programming in Blood Cancers
Bonifer, C., Cockerill, P. N., & Ptasinska, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_22
erythroid/megakaryocyte development HOXA10 is a critical regulator for hematopoietic stem cells and
Wutz, A., Sigvardsson, M., Karlsson, S., Magnusson, M., Brun, A. C. M., Miyake, N., Larsson, J. T., Ehinger, M., & Björnsson, J. M. (2013)
Verbiest, T. (2016) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-zg75ozpqw
The Role of PU.1 in Lipid Metabolism and Cell Cycle Regulation in Myeloid Progenitor Cells
Rhee, J. (2018) · Scholarship@Western (Western University)
Biology of acute myeloid leukemia stem cells: the role of CITED2 and mitochondrial activity
Mattes, K. (2019) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.98637951
Unveiling novel functions of the trascriptional repressor HDAC7 in B lymphocyte development
Azagra, A. (2019) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Etani, R., Ojima, M., Ariyoshi, K., Fujishima, Y., & Kai, M. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1793018
Rôle du facteur de transcription hsf1 dans l’érythropoïèse du poisson zèbre
Campario, H. (2020) · theses.fr (ABES) · doi:10.70675/69397145z8394z458bzae7fz6c4c8507b5db · Cited by 1
Characterisation of the BCAT1 CXXC motif in Acute Myeloid Leukaemia
Hillier, J. (2020) · Worcester Research and Publications (University of Worcester) · Cited by 1
Gene Repression and Cell Cycle Regulation by PU.1 in Acute Myeloid Leukemia
Ziliotto, R. G. (2013) · Scholarship@Western (Western University)
Takahashi, S. (2021) · Journal of Molecular Signaling · doi:10.5334/1750-2187-15-1
Heim, S., & Mitelman, F. (2010) · Wiley eBooks · doi:10.1002/9781118010136.ch6
Mahmoodi, M. H., Aghdam, R., & Eslahchi, C. (2020) · Research Square · doi:10.21203/rs.2.21700/v1
Ultimate Precision: Targeting Cancer But Not Normal Self-Replication
Velcheti, V., Schrump, D. S., & Saunthararajah, Y. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_11
Genome-Wide Approaches to Defining Macrophage Identity and Function
Fonseca, G. J., Seidman, J. S., & Glass, C. K. (2017) · ASM Press eBooks · doi:10.1128/9781555819194.ch30
Batista, C. R., & DeKoter, R. P. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101960-1
Tomlinson, I. P. M. (2009) · Springer eBooks · doi:10.1007/978-3-540-37654-5_16
Jones, R. E., Hill, M., & Taylor, P. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17705.1
Tatetsu, H., Ueno, S., Hata, H., Yamada, Y., Takeya, M., Mitsuya, H., Tenen, D. G., & Okuno, Y. (2023) · doi:10.1158/0008-5472.c.6495728
Self-citationAivalioti, M. M., Bartholdy, B., Pradhan, K., Bhagat, T. D., Zintiridou, A., Jeong, J. J., Thiruthuvanathan, V. J., Pujato, M. A., Paranjpe, A., Zhang, C., et al. (2023) · doi:10.1158/2643-3230.c.6550979
Aivalioti, M. M., Bartholdy, B., Pradhan, K., Bhagat, T. D., Zintiridou, A., Jeong, J. J., Thiruthuvanathan, V. J., Pujato, M. A., Paranjpe, A., Zhang, C., et al. (2023) · doi:10.1158/2643-3230.c.6550979.v1
Cellular carcinogenesis in preleukemic conditions:drivers and defenses
Ueda, K., & Ikeda, K. (2023) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.2023-17
“Moreover, we crossbred Mdmx - Tg mice with preleukemic murine models, such as PU.1 knock - down mice (URE - / - ) 128) , Tet2 - / - mice, Tet2 - /+ mice 129) , and Flt3 ITD/WT mice 130) .”
Gregoricchio, S. (2021) · theses.fr (ABES) · doi:10.70675/f1d71abdzfa19z4e95z89e6zdfa431de5448
Waliullah, A. S. M., Qiu, K., Dziegielewska, B., Tran, M. L., Nguyen, N. N., Wang, L., Pan, A., Segovia, N., Ummarino, S., Zhang, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.19.638695
“Reduced expression of PU.1 disrupts myeloid cell differentiation, resulting in the development of acute myeloid leukemia (AML) (Cook, McCaw et al. 2004, Rosenbauer, Wagner et al. 2004).”
Self-citationAntagonistic effects of PU.1 on Gfi-1B-induced erythroid colony formation in human cord blood cells
Manabe, N., Sakurai, T., Kihara‐Negishi, F., Nakazawa, Y., Yamada, T., Iwama, A., & Oikawa, T. (2025) · Cellular and Molecular Biology · doi:10.14715/cmb/2025.71.3.6
Metadata
- Authors
- Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Dartmouth College (US)
- Corresponding author
- Tenen, Daniel G
- ORCID
- Venue
- Nature Genetics
- Published
- 2004-05-16
- Volume
- 36
- Issue
- 6
- Pages
- 624-630
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2060618743
- Cited by
- 506
- References
- 28
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 11 · 2023: 21 · 2022: 10 · 2021: 25 · 2020: 13 · 2019: 22 · 2018: 25 · 2017: 24 · 2016: 19 · 2015: 18 · 2014: 27 · 2013: 36 · 2012: 28
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Dartmouth College
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- National Cancer Institute (P30CA023108)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- acute myeloid leukemia, PU.1, transcription factors, hypomorphic allele, myeloid development, myeloid differentiation, leukemogenesis
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Bone Marrow, Hematopoiesis, Humans, Karyotyping, Mice, Inbred C57BL, Mice, Mutant Strains, Mice, Transgenic, Proto-Oncogene Proteins, Spleen, Leukemia, Myeloid, Acute, Trans-Activators, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.